Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene Vaginal
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvovaginal Atrophy
Conditions
Vulvovaginal Atrophy
Trial Timeline
Jan 9, 2020 → Nov 30, 2020
NCT ID
NCT04232813About Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene Vaginal
Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene Vaginal is a phase 3 stage product being developed by Novo Nordisk for Vulvovaginal Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT04232813. Target conditions include Vulvovaginal Atrophy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04232813 | Phase 3 | Completed |
Competing Products
10 competing products in Vulvovaginal Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Fluconazole | Pfizer | Phase 3 | 76 |
| Clotrimazole vaginal tablet + Fluconazole | Bayer | Approved | 82 |
| SCY-078 + Fluconazole | Scynexis | Phase 2 | 44 |
| Ibrexafungerp | Scynexis | Phase 3 | 69 |
| Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tablet | Scynexis | Phase 3 | 69 |
| Ibrexafungerp | Scynexis | Phase 1 | 25 |
| Estradiol + Placebo | TherapeuticsMD | Phase 3 | 69 |
| Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB) | Matinas Biopharma | Phase 2 | 44 |